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Genital herpes is caused by herpes simplex virus 1 (HSV-1) and HSV-2, and its incidence is constantly increasing in the human
population. Regardless of the clinical manifestation, HSV-1 and HSV-2 infections are highly transmissible to sexual partners and
enhance susceptibility to other sexually transmitted infections. An effective vaccine is not yet available. Here, HSV-1 glycopro-
tein B (gB1) was delivered by a feline immunodeficiency virus (FIV) vector and tested against HSV-1 and HSV-2 vaginal chal-
lenges in C57BL/6 mice. The gB1 vaccine elicited cross-neutralizing antibodies and cell-mediated responses that protected 100
and 75% animals fromHSV-1- and HSV-2-associated severe disease, respectively. Two of the eight fully protected vaccinees un-
derwent subclinical HSV-2 infection, as demonstrated by deep immunosuppression and other analyses. Finally, vaccination pre-
vented death in 83% of the animals challenged with a HSV-2 dose that killed 78 and 100% naive andmock-vaccinated controls,
respectively. Since this FIV vector can accommodate two or more HSV immunogens, this vaccine has ample potential for im-
provement andmay become a candidate for the development of a truly effective vaccine against genital herpes.
Genital herpes is a recurrent, life-long viral infection caused byherpes simplex virus 1 (HSV-1) andHSV-2. The incidence of
this infection varies from country to country, but at least 50 mil-
lion people in the United States (between 15 and 20% of the adult
population) have genitalHSV infection (10), with an increment of
at least 30% in the last 25 years (22) and in spite of a possible
reduction in recent years (66, 67). The incidence is also escalating
worldwide, including low-income countries where the epidemiol-
ogy has been investigated (41). Nomatter whether the infection is
clinically manifested or asymptomatic, the virus replicates and is
shed for relatively long periods of time in the genital mucosa epi-
thelia and is eventually transmitted to sexual partners and off-
spring. Recognized vehicles of transmission are saliva, semen, cer-
vical fluid, or vesicle fluid from active lesions (63). In general,
primary and recurrent infections are so mild that go unnoticed
but, depending on immune status, gender, and age, patients may
develop clinical signs that require hospitalization in certain cases.
Herpes lesions developwithin 2 to 20 days after contact, can occur
anywhere in the genital area, and are characterized by small blis-
ters that may ulcerate and take up to 4 weeks to heal. The infected
area is usually painful and may itch, burn or tingle, during the
outbreak (13, 47). Women tend to have more severe disease and
higher rates of complications associated with primary infection;
HSV-2 seropositivity increases the risk of acquiring other sexually
transmitted infections, including the human immunodeficiency
virus (HIV) infection, and developing cervical cancer (1, 53). An-
tivirals are available but are only effective postexposure and are
unable to avoid latency and reactivation of infections (11). Among
pre-exposure measures, anti-HSV microbicides are an apt option
but, except for an HIV reverse transcriptase-inhibitor also effec-
tive against HSV (2), those under testing have a narrowwindow of
efficacy that strictly depends on time from exposure and infec-
tious dose (65). Anti-HSV-1 and anti-HSV-2 vaccines would thus
be themost effective pre-exposuremeans to contain virus dissem-
ination.
Over the last 2 decades, numerous efforts have been made to
develop effective vaccines against genital herpes. The strategies
tested included genetically attenuated live virus, whole inactivated
virion preparations, recombinant subunit vaccines, gene-delivery
vehicles expressing structural or nonstructural HSV antigens, and
DNA plasmid expressingHSV antigens (reviewed in references 17
and 38).Most of these approaches failed during animal study or in
early phases of human trials, but a few have received the more
consideration since they were able to reduce the rate of acquiring
HSV-2 genital infection in HSV-seronegative women (45). These
results offered hope that vaccination againstHSV-2 is possible but
also showed that improvement of current and development of
novel concepts were clearly necessary (17). Notably, a recent vac-
cination trial using HSV-2 glycoprotein D and two adjuvants and
including 8,323 young seronegative women was effective at pre-
venting HSV-1 but not HSV-2 infection and/or disease (5).
Among novel strategies, delivery of the immunogens by lenti-
viral vectors proved particularly effective to vaccinate against in-
fectious diseases and cancer (26, 31, 37, 48). Compared to vectors
derived from other viruses, those derived from lentiviruses offer
advantages such as low or null preexisting population immunity,
ability to transport one or more heterologous genes (transgenes),
delivery of the transgenes to replicating and quiescent cells (trans-
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duction), and prolonged transgene expression. Vectors derived
fromHIV-1 are among the most efficient, but potentially residual
pathogenicity has hitherto restricted their clinical use (19). The
feline immunodeficiency virus (FIV) may be a good alternative as
a vector. FIV is a lentivirus in domestic cats and similar to HIV-1
in many respects, including genomic organization, but is unable
to infect humans (20). Vectors derived from FIV have been suc-
cessfully used to transduce primary cells from feline and nonfeline
species (24, 52), including humans (60), and proved safe in vitro
and in vivo (4, 8, 52).
Here, we used an FIV vector to deliver and trigger a specific
immune response against the HSV-1 glycoprotein B (gB1) that,
together with other glycoproteins, serves as viral receptor (7, 55,
57). The nonmuscle myosin heavy chain IIA (NMHC-IIA), a sub-
unit of nonmuscle myosin IIA (NM-IIA), has been recently pro-
posed as a gB1 cellular receptor (3). Since NM-IIA is ubiquitously
expressed in various human tissues and cells, gB1-NMHC-IIA
interaction may be responsible for the HSV-1 broad host range in
vitro (62). Eliciting specific anti-gB1 immune responses may thus
result in a significant reduction in viral infectivity. The gB1 recom-
binant FIV vector was tested in mice against vaginal challenges
with fully virulent HSV-1 and HSV-2 isolates. Vaccination trig-
gered gB1-specific humoral and cell-mediated immune responses
that cross-protected animals from primary and recurrent infec-
tions with sublethal and lethal challenge doses.
MATERIALS AND METHODS
Cells. Human epithelial 293T cells were grown in Dulbecco modified
Eagle medium (DMEM) supplemented with 10% heat-inactivated fetal
calf serum (FCS), penicillin (100 U/ml), streptomycin (10 g/ml), and
L-glutamine (2 mM) (all from Sigma-Aldrich, Milan, Italy) (complete
DMEM).Murine fibroblastNIH3T3 and simian epithelial Vero cells were
grown in Eagle minimum essential medium supplemented as described
above (complete EMEM).
Mice and challenge viruses. Inbred C57BL/6 mice were purchased
from Harlan Italy (Correzzana, Milan, Italy) and housed and bred in a
biosafety level 3 animal facility approved for mouse detention and repro-
duction. Animals were maintained on a 12/12-h dark/light cycle and ma-
nipulated according to European Union and Italian guidelines and legis-
lation. All manipulations were performed under deep anesthesia using 20
mg of 2,2,2-tribromoethanol (Sigma-Aldrich)/hg inoculated intraperito-
neally. The project was approved by the University of Pisa Ethical Com-
mittee for Animal Research.
The neurovirulent strains LV (59) and MS (American Type Culture
Collection, catalog no. VR-540) of HSV-1 and HSV-2, respectively, were
used for challenge. These strains were expanded in semiconfluent T-175
flasks (BD Biosciences, Milan, Italy) of Vero cells. The flasks were inocu-
lated with 1 PFU of HSV-1 or HSV-2/cell in complete EMEM, and after 6
h fed fresh EMEM, and cultured for further 2 to 3 days or until cell lysis.
Culture fluids were then spun at 1,200  g, and the pellets were freeze-
thawed three times to release intracellular virions. After clarification at
600  g for 5 min, the supernatants were pooled, 0.45-m-pore-size
filtered, and ultracentrifuged at 50,000 g for 90 min to concentrate the
virus. Pelleted virus was resuspended in saline, at 1/100 of the initial vol-
ume, and stored in small aliquots at80°C until use. Plaque titration of
the viral stocks was carried out on Vero cells. The cells were seeded (1.2
105/well) in 48-well plates and 1 day later inoculated with 10-fold dilu-
tions (range, 103 to 1010) of the viral stocks in triplicate. After 6 h, the
medium was replaced with complete EMEM plus 1% methylcellulose
(Sigma-Aldrich), and the plates were incubated for 2 to 3 days. The cells
were then fixed with 10% formalin and stained with gentian violet, and
viral plaques were counted under a light microscope. Titers are expressed
as PFU/ml.
Since age and estrous cycle are known to influence the susceptibility to
genital herpes (58), in vivo titration of the viral stocks was performed in
mice at age 11 weeks, that is, at the age we had planned to perform the
challenge in the vaccination experiments, and with their estrous cycles
synchronized. Cycle synchronization was achieved with 2 mg of depot
medroxyprogesterone acetate (Depo-Provera; Pfizer Italia, Latina, Italy)
inoculated subcutaneously 5 days before infection. To facilitate virus ab-
sorption, the vaginas were preswabbed with a dry-tipped swab immedi-
ately prior to the instillation of 10-fold dilutions of the viral stocks. The
animals were then examined daily for signs of infection. These usually
showedup at day 5 or 6with local erythema andulcers and rapidly evolved
into manifestations of nervous system involvement (arched backs, feeble
movements, and paralysis of one or both hind limbs). The latter stage was
usually irreversible, and death occurredwithin 1 to 2 days. Titrations were
performed using five to eight animals/virus dilution. The 50% lethal dose
(LD50) was calculated according to the Reed and Muench formula (46).
Animals that survived despite paralysis or other irreversible lesions were
euthanized by cervical dislocation under anesthesia.
Construction of vaccine vector and generation of vector particles.
gB1 gene was amplified by PCR from pTZ18U-gB1 (33) using the primers
BglII-HSV1F (5=-ATAGATCTCTGTCCGCTGGTG-3=) and BglII-gBR
(5=-GAAGATCTTCTCACAGGTCGTCCTCGTCGGCGTC-3=) and de-
naturation at 94°C for 2 min, followed by 25 cycles of 94°C for 30 s, 56°C
for 30 s, and 72°C for 3 min, with a final extension at 72°C for 7 min.
Amplification productwas digestedwithBglII enzyme and cloned into the
multiple cloning site of the LAW34 plasmid (43). The resulting pLAW-
gB1 construct was sequenced for gB1 correct insertion and absence of
mutations.
Vector particles delivering gB1 (vLAW-gB1), green fluorescent pro-
tein (GFP; vLAW-GFP), or vector backbone alone (vLAW) were gener-
ated. These were produced by cotransfecting the respective plasmids with
packaging penv1, which provided Gag and Pol, and pRD114/TR or
pVSV-G,which provided the envelope glycoprotein (Env). RD114/TR is a
chimeric Env with the surface and transmembrane regions of the feline
endogenous retrovirus RD114 fused with the cytoplasmic tail of an am-
photropic murine leukemia virus (50). VSV-G is the glycoprotein G of
vesicular stomatitis virus. Genomic maps of the pLAW, penv1, and Env
constructs are shown in Fig. 1A, while detailed descriptions are available
elsewhere (43). Cotransfection was performed in 293T cells (3  106)
using 35 g of plasmid DNA and a 4:2:1 vector/pEnv1/Env ratio. DNA
was diluted in 700l of 150mMNaCl and added to amixture of 600l of
150 mM NaCl and 100 l of 10 M polyethyleneimine (Sigma-Aldrich).
After 15 min at room temperature, the DNA mixtures were added to the
cells, and the medium was replaced with complete DMEM 6 h later. Vec-
tor supernatants were collected 48 to 72 h posttransfection, 0.45-m-
pore-size filtered, titrated, and stored in small aliquots at80°C until use.
Cell transductionand titrationof vectorpreparations.Transduction
was performed in 7 104 293T and 5 104 NIH 3T3 cells seeded the day
before in 24-well plates. After 24 h, the mediumwas replaced with 1 ml of
vector suspension diluted to contain10 vector transduction units (TU)
per cell. Vector titers were determined by transducing 7 104 293T cells
with serial 10-fold dilutions of vLAW-GFP supernatants. At day 2 post-
transduction, the cells were harvested, and GFP-positive cells were
counted by flow cytometry with a FACScan (BD Biosciences). Dilutions
were tested in triplicate, and titers were expressed in TU/ml. Equivalent
vLAW-gB1 and vLAW TU/ml values were obtained by normalizing these
and titrated vLAW-GFP supernatants for FIV p25 capsid protein and
LAW RNA genome copies as described previously (43). On average, vec-
tor titers ranged between 2 106 and 5 107 TU/ml.
Vaccination, challenge, follow-up, and immunosuppression. The
immunizing protocols started when themice were 5 weeks old. Groups of
animals were inoculated with vLAW-gB1 (vaccinees) or vLAW (mock
vaccinees) or left untreated (naive controls). Inoculationswere performed
intradermally in the hind footpad (50 l of vector) and tail base (100 l).
These immunization routes were selected in the attempt to facilitate cell-
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mediated immune responses (23, 69). No local or systemic adverse reac-
tions were observed. Elicited immune responses were analyzed in blood
(collected by cardiac puncture), spleen, lymph nodes, and bone marrow
of randomly selected vaccinated and mock-vaccinated animals. Tissues
were immediately processed or stored at80°C until use.
Challenge with HSV-1 or HSV-2 was performed via vagina following
estrous cycle synchronization as described above. The challenge dose was
1 LD50 (roughly corresponding to 10
6 PFU) in all experiments except the
last one, in which 10 LD50 (10
8 PFU) were used. All animals were moni-
tored for about 3 weeks postchallenge (p.c.). Clinical signs of infection
were graded according to a five-point scale: 0, no signs; 1, slight genital
erythema and/or edema; 2, papules, ulcers and/or swelling; 3, fused ulcers,
purulent genital lesions and/or hind limb paralysis; and 4, death (40).
Immunosuppression was achieved with an intraperitoneal bolus of
350 mg of cyclophosphamide (CY; Baxter, Rome, Italy)/kg. To check for
immune cell depletion, mice were bled the following day retro-orbitally;
circulating CD4 and CD8T lymphocytes were labeled with fluorescein
isothiocyanate (FITC)-conjugated monoclonal antibodies (eBioscience,
SanDiego, CA) and counted using flow cytometry as described previously
(42).
gB1 expression. Transfected and transduced 293T and NIH 3T3 cells
were examined for gB1 expression by Western blotting (WB). The cells
were lysed withWB lysis buffer (50 mMTris [pH 7.5], 150 mMNaCl, 1%
Triton, 1 mM EDTA, 0.1% protease inhibitor, 5 mg of MG123 protea-
some inhibitor [Merck, Milan, Italy]/ml). Proteins were separated on a
10% sodium dodecyl sulfate (SDS)-polyacrylamide gel and transferred
onto a nitrocellulose membrane (GE Healthcare, Milan, Italy). Mem-
brane was blocked with 3% skim milk (Sigma-Aldrich) in phosphate-
buffered saline (PBS)–1%Tween 20 and probed with anti-gB1 polyclonal
antibody (9) diluted 1:4,000 in 1% skimmilk and horseradish peroxidase
FIG 1 Genomic maps of vector, packaging, and Env plasmids used to generate vLAW-gB1 and analysis of gB1 expression in vitro. (A) Schematic organization
of plasmid vector pLAW-gB1, packaging penv1, RD114/TR, a chimeric Env glycoprotein with surface and transmembrane regions of feline endogenous
retrovirus RD114 and cytoplasmic tail ofmurine leukemia virus (50), andVSV-G, the Env glycoprotein G of vesicular stomatitis virus. pLAW-gB1was produced
by cloning full-length HSV-1 glycoprotein B (gB1) into pLAW34. A full description of pLAW34, penv1, and Env constructs is available elsewhere (43). CMVp,
CMV promoter; , packaging site; RRE, Rev-responsive element; WPRE, woodchuck hepatitis posttranscriptional regulatory element. (B) WB analysis of gB1
expression as evaluated in transfected (left panel) or transduced (right panel) human 293T and murine NIH 3T3 cell lines. Transfection was performed with
pLAW-gB1 alone. Transductionwas carried outwith vLAW-gB1 pseudotypedwith either RD114/TR, orVSV-G. Arrow indicates gB1 protein band. K andK,
uninfected and HSV-1-infected Vero cells, respectively. Naive, mock-transduced 293T or NIH 3T3 cells. Mk, high-range SDS-PAGE standard (Bio-Rad).
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(HRP)-conjugated anti-rabbit secondary antibody diluted 1:2,000 in
0.5% skim milk. Detection was carried out using an HRP substrate kit
(Bio-Rad, Milan, Italy).
Humoral responses. Elicited anti-gB1 antibody (gB1-Ab), total anti-
HSV antibody, and neutralizing antibody (NAb) were examined by WB,
enzyme-linked immunoassay (ELISA), and neutralization assay. WB was
performed using HSV-1- or HSV-2-infected Vero cells as a substrate.
Briefly, 106 cells were seeded the day before in a T-75 flask, infected with
10 PFU of HSV-1 or HSV-2/cell, and scraped off at 24 h postinfection.
Cells were lysed with WB lysis buffer, aliquoted in 20-l portions, and
stored at80°C. WB was carried out as described above except that pro-
tein lysate was separated on an 8% SDS–polyacrylamide gel, and murine
sera and anti-mouse-HRP conjugates were used at dilutions of 1:100 and
1:1,000, respectively. ELISA was performed with murine sera diluted
1:100 and an Enzygnost anti-HSV/IgG test plate assay (Siemens, Milan,
Italy), which contains antigens purified from chronically HSV-infected or
uninfected simian kidney cells. Detection was carried out with biotinylated
anti-mouse IgG antibody diluted 1:1,000 (eBioscience), extravidin-HRP di-
luted 1:5,000 (Sigma-Aldrich), and 3,3=,5,5=-tetramethylbenzidine-hydro-
gen peroxide as a substrate (Pierce, Rockford, IL). Plates were read at 490
nm. Anti-HSV-1 and -HSV-2 NAbs were assayed by plaque assay. Heat-
inactivated sera were preadsorbed in Vero cells and diluted 1:10 to 1:80 in
a 2-fold fashion in complete EMEM. The diluted samples were incubated
with 100 PFU of HSV-1 or HSV-2 at 37°C for 1 h and then added to Vero
cells (1.2 105/well) seeded the day before in 48-well plates. After 6 h at
37°C, themediumwas replaced with 200l of complete EMEM, 5% FCS,
and 3%methylcellulose, and the plates were further incubated for 48 to 72
h. The cells were stained, and lysis plaques were counted as for the in vitro
HSV titration. The percent neutralization was calculated using the for-
mula (1 the number of infected cells in the presence of serum dilution/
the number of cells incubated with virus alone) 100. Each serum dilu-
tion was tested in triplicate.
Cell-mediated immune response. T lymphocytes secreting gamma
interferon (IFN-) upon recognition of a specific gB1T-cell epitope (gB1-
TL) were measured by intracellular staining. Single-cell suspensions
from spleen and iliac lymph nodes were prepared by mechanical disrup-
tion. Bone marrow-derived cells were obtained by flushing out cells from
femurs. Cells were washed twice with RPMI 1640 medium (Sigma-Al-
drich) supplemented as described above, counted, and placed (3 106) in
FACScan tubes (Sarstedt, Verona, Italy). Samples were stimulated with 1
g of gB1 T-lymphocyte epitope (498SSIEFARL505) (25)/ml or scrambled
peptide ASFLRSEI (both peptides were synthesized by Espikem, Florence,
Italy). Nonspecific stimulation with 5 ng of phorbol myristate acetate/ml
and 2g of ionomycin/ml (both from Sigma-Aldrich) served as a positive
control. Brefeldin A (5 g/ml; Sigma-Aldrich) was added 1 h after stim-
ulation; 5 h later, the cells were washed once with fluorescence-activated
cell sorting (FACS) buffer (0.2% bovine serum albumin and 0.1% sodium
azide in PBS [pH 7.4]) and fixed with FACS Fix (FACS buffer and 1%
formaldehyde). After further washes, the cells were incubated with 0.1%
saponin (Sigma-Aldrich) and labeled with 50 g of FITC-conjugated
anti-mouse CD8 and phycoerythrin-conjugated anti-mouse-IFN- anti-
body (eBioscience)/ml. Labeled cells were counted by flow cytometry, and
the data were analyzed using the CellQuest version 2 software (BD Bio-
sciences).
HSV-2 DNA genome in genital swabs and tissues. Vaginal swabs
were soaked in 600l of PBS at room temperature for 15min, and cervical
epithelial cells were pelleted by centrifugation. HSV DNA was extracted
with a QIAamp DNA minikit as recommended by the manufacturer
(Qiagen, Milan, Italy). Sacral nerves and genital ganglia were protease
digested, and DNA was extracted as described above. Molecular analysis
was carried out by using an HSV-2-specific nested PCR as described pre-
viously (16, 21). The first and second PCR primer pairs were 6AF (5=-TC
AGCCCATCCTCCTTCGGCAGTA-3=)/6BR (5=-GATCTGGTACTCGA
ATGTCTCCG-3=) and 6CF (5=-AGACGTGCGGGTCGTACACG-3=)/
6DR (5=-CGCGCGGTCCCAGATCGGCA-3=), respectively. The am-
plification profile (denaturation at 94°C for 2 min; five cycles of 94°C for
1min, 56°C for 1min, and 72°C for 1min; 40 cycles of 94°C for 45 s, 56°C
for 30 s, and 72°C for 1 min; final extension at 72°C for 15 min) was the
same for both PCRs, except that the second amplification profile was
decreased to 30 cycles. Amplicons were examined on a 1% agarose gel.
Statistics. Statistical analyses were performed using SPSS 15.0 soft-
ware (SPSS, Inc., Chicago, IL). The Fisher exact test was applied to eval-
uate heterogeneity of contingency tables. P values of0.05 were consid-
ered statistically significant. One-way analysis of variance (ANOVA) was
applied to evaluate differences among means of different groups. Tukey’s
multiple-comparison test was used to determine which means were sig-
nificantly different.
RESULTS
Vector LAW-gB1 construction and in vitro characterization.
Vector LAW-gB1 delivers gB1 cloned into the LAW34 backbone.
LAW34 is a self-inactivating vector derived from the FIV strain
Petaluma. It contains theminimal FIV residues necessary for viral
RNA encapsidation into progeny particles, importation into the
nucleus, and integration in the host cell genome. To comply with
today’s safety and efficiency standards (26), LAW34 has both long
terminal repeats inactivated by an internal deletion in U3, thus
minimizing the risk of insertional mutagenesis. Other salient fea-
tures of LAW34 include the presence of a cytomegalovirus (CMV)
promoter and a woodchuck hepatitis virus posttranscriptional
regulatory element, which allowed us to drive the expression of
the gene of interest and to stabilize its mRNA, respectively (43).
Maps of the LAW-gB1, of the packaging penv1, and of the Env
constructs that were used to generate pseudotyped particles (see
below) are shown in Fig. 1A.
Analysis of gB1 expression in vitro was preliminarily evaluated
in pLAW-gB1 transfected 293T and NIH 3T3 cells. Cells were
examined at day 2 posttransfection by WB with a gB1 polyclonal
antibody. As shown in Fig. 1B, the WB profile was indistinguish-
able from that of a protein lysate ofHSV-1-infected Vero cells that
were run in parallel as a positive control. This result demonstrated
that gB1 was encoded in full and correctly processed in both 293T
and NIH 3T3 cells.
In previous work we demonstrated that it is possible, to some
extent, to retarget vLAW34 by changing Env. For instance, using
the chimeric RD114/TR, i.e., the surface and transmembrane pro-
tein of the feline endogenous retrovirus RD114 fused with the
cytoplasmic tail of the murine leukemia virus (50), led to a high
efficiency of transduction for ex vivo immaturemurine bonemar-
row-derived dendritic cells (DCs). In contrast, ex vivo murine T
lymphocytes were better transduced by VSV-G-pseudotyped par-
ticles (43).We therefore considered it to be of interest to compare
the properties of LAW-gB1 pseudotyped with either RD114/TR
(vLAW-gB1/RD) or VSV-G (vLAW-gB1/VSV). 293T cells were
equally transduced by the two vectors (ca. 80%). In contrast, NIH
3T3 cells were more efficiently transduced with vLAW-gB1/RD
(65%) than with vLAW-gB1/VSV (30% [data not shown]). As a
consequence, in transduced NIH 3T3 cells the gB1 expression
level was similarly affected (Fig. 1B). In either case, however, gB1
was produced full length and for at least 2weeks posttransduction,
suggesting that LAW-gB1 DNA integrated into the cell genome
(Fig. 1B and data not shown).
Vaccination experiments using HSV-1 as a challenge. In a
first pilot experiment not reported in detail for brevity, groups of
eightmicewere immunizedwith 105 or 106 TUof vLAW-gB1/RD-
or vLAW-gB1/VSV-inoculated twice in the footpads 1 week apart.
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Similar groups ofmice were given 106 TU of vLAW/RD or vLAW/
VSV and served asmock-vaccinated controls. Oneweek after each
inoculation, two animals per group were sacrificed and examined
for gB1-Ab and gB1-TL in the blood. As expected, the mock-
vaccinated animals showed no detectable anti-gB1 immunity at
any time, and the same was true for those given 105 TU of the
immunogens. In contrast, the animals immunized with 106 TU of
vLAW-gB1/RD or vLAW-gB1/VSV consistently showed both
gB1-Ab and gB1-TL. Interestingly, whereas gB1-Ab levels were
uniformly low regardless of the immunogen used, those of gB1-
TL were highest in mice given vLAW-gB1/RD, suggesting that
this immunogenmight have beenmore effective at triggering cell-
mediated immunity. Three weeks after the last immunizing dose,
four animals per group and six naive animals were challenged
intravaginally with 1 LD50 of HSV-1 as described inMaterials and
Methods. All naive and mock-vaccinated mice became obviously
sick starting fromday 6 p.c. The animals injectedwith 105 TUwere
also totally unprotected. On the other hand, two of four mice
given 106 TUof vLAW-gB1/RD and one of fourmice given 106 TU
of vLAW-gB1/VSV showed no clinical signs. Furthermore, the
animals in both of these two groups that became sick uniformly
developed milder clinical manifestations than did the controls. It
was thus tentatively concluded that both vLAW-gB1/RD and
vLAW-gB1/VSV were promising immunogens, provided that
they were administered at doses of at least 106 TU.
In the subsequent experiment, groups of 14 mice were treated
as described above except that, in an attempt to potentiate the
extent of protection, they also received a third dose of immuno-
gens and mock immunogens (again, 106 TU) administered at the
base of the tail 2 weeks after the second footpad inoculation (Fig.
2). Anti-gB1 immunity was monitored in three mice/group sacri-
ficed 1 week after the first and second immunizations and at chal-
lenge (i.e., 3 weeks after the third inoculation). Similar to what
was observed in the previous experiment, vLAW-gB1/RD- and
vLAW-gB1/VSV-vaccinated mice had comparably low gB1-Ab
levels after the first two immunizations; however, at the time of
challenge, animals given vLAW-gB1/VSV showed a substantial
increase in antibody titers, whereas the ones in the vLAW-gB1/RD
group did not (Fig. 3A). The development of gB1-TL also dif-
fered depending on the immunogen used: in the mice vaccinated
with vLAW-gB1/RD, gB1-TL developed very promptly, peaked
after the second dose, and by the time of challenge had substan-
tially decreased. In contrast, in animals vaccinated with vLAW-
gB1/VSV the gB1-TL developed more slowly, so that the peak
was observed only at the time of challenge. Thus, by this time, the
two groups had equivalent numbers of gB1-TL in the blood. As
expected, mock-vaccinated mice were constantly negative for
both gB1-Ab and gB1-TL (Fig. 3A).
Finally, the remaining five animals per group and an equal
number of naive mice were challenged with HSV-1 exactly as de-
scribed above. At day 6 p.c., all naive mice and four of the five
mock-vaccinated mice were overtly sick, with clinical signs that
scored 2 or more by days 8 to 10. Four of these animals (one naive
and three mock vaccinees) died between days 10 and 12, whereas
in the others the infection subsided so that all appeared fully re-
covered at the termination of the experiment, i.e., at day 15 p.c. In
the vLAW-gB1/RD vaccinees the outcome of challenge was indis-
tinguishable from the controls: all animals developed severe signs
of disease, and 1 died at day 10 p.c. In contrast, in the vLAW-gB1/
VSV vaccinated group, three of five animals remained completely
disease-free throughout the observation period, and the other 2
only showed some redness around the vagina that disappeared
within 2 days (Fig. 3B). These results were a clear indication that
vLAW-gB1/VSV, possibly due to its wider spectrum of cells trans-
duced, was amuch better protective immunogen thanwas vLAW-
gB1/RD. Thus, the subsequent experiments were conducted with
vLAW-gB1/VSV alone.
Vaccination experiments using HSV-2 as a challenge. In the
FIG 2 Timeline and details of vaccination, challenge, and immunological and follow-up analyses. Empty arrows indicate inoculations of 106 TU/dose of vaccine
vLAW-gB1 and mock-vaccine vLAW. Empty triangles indicate the time at which randomly selected animals were sacrificed and examined for the indicated
immunological parameters. At 3 weeks after the last vaccine inoculation, the animals were challenged via vagina with 1 or 10 LD50s of HSV-1 or HSV-2.
Challenge, indicated by solid arrow, was preceded by the inoculation of depot medroxyprogesterone acetate (Depoprovera, gray arrow) to synchronize the
estrous cycle. Animals were monitored postchallenge for clinical signs of infection for about 3 weeks and, at termination, examined as detailed in the gray box.
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first of the experiments using HSV-2 as a challenge, the immuno-
gen was vLAW-gB1/VSV, the mock immunogen vLAW/VSV, the
experimental plan the same depicted by Fig. 2, and the intravagi-
nal challenge was conductedwith 1 LD50 ofHSV-2. Of the 30mice
that were given the immunogen and the 25 that received themock
immunogen, 14 and 13, respectively, were used to monitor the
anti-gB1 immune response at the three times indicated in Fig. 2
(three to five animals per group per time point). These analyses
showed that, while the mock vaccinees had no detectable re-
sponses, the vaccinees had responded exactly as observed with the
same inocula in the previous experiment, with regard to both the
kinetics and the levels of gB1-TL and gB1-Ab generated (data not
shown).
The HSV-2 used for challenge was known to be especially vir-
ulent. Thus, after the challenge of the 12mock vaccinees and of the
19 naive mice that were used as unmanipulated controls, only 1
(8%) and 2 (11%), respectively, remained free of signs of infection
(Fig. 4). All of the others became clearly sick, with clinical pictures
that in most cases had a clear tendency to worsen with time; as a
result, when the experiment was terminated at 20 days p.c., of the
17 naive mice and 11 mock vaccinees that had developed clinical
signs, only 8 (47%) and 2 (18%), respectively, had apparently
recovered, while the others had either succumbed or were still
clearly diseased. In sharp contrast, the outcome of challenge was
much less severe in the vaccinees: of the 16 animals in the group,
half resisted the challenge completely, 5 (31%) developed very
mild infection (clinical score	 2), which promptly subsided, and
only 3 (19%) developed severe clinical manifestations that led to
their euthanasia (Fig. 4 and Table 1). Statistical analysis showed
that the proportion of animals which had developed lesions of any
severity postchallenge was significantly smaller in the vaccinated
group than in the naive plus the mock-vaccinated group (P 

0.003) and that the same was true, at a much higher level of sig-
nificance, for the proportion of animals with lesions scoring 2 to 4
(P	 0.0001).
In the next experiment, mice were immunized exactly as de-
scribed above, but the HSV-2 dose was 10 LD50. In the 15 mice
FIG 3 Analysis of elicited immunity and outcome of HSV-1 challenge in
animals vaccinated (LAW-gB1) or mock-vaccinated (LAW) with the respec-
tive vector pseudotyped with RD114/TR or VSV-G. (A) The top panels show
the levels of anti-gB1 antibodies (gB1-Ab), measured with a commercial anti-
HSV antibodies ELISA kit; the lower panels show the percentages of IFN--
secreting CD8 T lymphocytes recognizing the gB1 T-lymphocyte epitope
498SSIEFARL505 (gB1-TL; continuous line) or scrambled peptide ASFLRSEI
(dotted line) were determined by intracellular staining of spleen cells stimu-
lated in vitro. IFN--secreting CD4 T lymphocytes were below cutoff or
undetectable. Empty and solid circles indicate LAW-gB1 and LAW animals,
respectively. Whiskers indicate the standard deviation. Dotted lines indicate
the cutoff, as calculated according to themanufacturer’s instructions (gB1-Ab)
or experimentally (gB1-TL). White and black arrows indicate inoculation of
above immunogens and challenge with HSV-1, respectively. (B) Percentages
of naive, LAW, and LAW-gB1 animals that remained disease-free after chal-
lenge with 1 LD50 HSV-1. n, Number of animals/group.
FIG 4 Outcome of challenge performed with 1 LD50 of HSV-2. Animals were
vaccinated (LAW-gB1) or mock vaccinated (LAW) with vector particles pseu-
dotyped with VSV-G. (A) Percentages of animals that remained disease-free
throughout the observation period. (B) Percentages of surviving animals. The
number of dead animals includes those that succumbed to the infection or
were euthanized following paralysis or other irreversible lesions. n, Number of
animals/group. One and two asterisks indicates significant differences relative
to vaccinated animals at P 0.03 and P 0.003, respectively.
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used as controls (9 naive and 6 mock vaccinated), this challenge
produced a very severe clinical picture: compared to the 1-LD50
challenge, the viral lesions became evident 3 to 4 days earlier, had
a more evident onset, and progressed more rapidly to score 3 to 4
(large ulcers and/or paralysis) and death (Fig. 5). Thus, by the end
of the experiment at day 24, only two naive mice (13% of total
controls) were still alive and had apparently resolved the infection.
All of the others had succumbed between days 10 and 12. Relative
to the dramatic picture observed in the controls, the six mice that
had been vaccinated with vLAW-gB1/VSV exhibited a much less
dramatic postchallenge outcome. Although one animal died at
day 10 p.c., three showed transient lesions that scored 2 or above,
one had modest redness around the vagina that lasted 1 day, and
one showed no lesions at all (Fig. 5). At the end of the experiment,
the difference in the proportion of vaccinated and control animals
with lesions scoring 2 to 4 was statistically significant at P
 0.003.
vLAW-gB1/VSVprotects both againstHSV-2 disease and in-
fection. The data presented above indicated that immunization
with vLAW-gB1/VSV reduced the clinical consequences of an
HSV-2 challenge; however, these findings were not informative as
towhether vaccination did so just by increasing the likelihood that
the infection remained subclinical or also by preventing infection
acquisition. In an attempt to shed light on this aspect, the eight
vaccinees that in the above experiment had remained completely
disease-free after challenge with 1 LD50 of HSV-2 were extensively
investigated for the presence of traces of ongoing or past infection.
First, vaginal swabs collected at the end of follow-up from these
micewere examined for the presence ofHSV-2 genomes by nested
PCR. Five vaccinees that in the same experiment had developed
transient lesions and five naive mice that in the same experiment
had become overtly sick were used as positive controls. However,
the PCR assay was positive only in three naive controls that still
presented with extensive genital lesions at the time of sampling
(Table 2), thus showing that the approach was not sufficiently
sensitive.
Sera then collected at days 30 p.c. from the eight protected
animals were examined by WB for the presence, gB1-Ab aside, of
antibodies recognizing other HSV proteins that might therefore
indicate that an infection had taken place. Sera from naive and
TABLE 1 Clinical status of animals challenged with 1 or 10 LD50s of HSV-2, as measured at the end of follow-up
a
Group
No. (%) of animals challenged with 1 LD50 No. (%) of animals challenged with 10 LD50
Total Sick or dead Recovering Healthy Total Sick or dead Recovering Healthy
Naive 19 11 (58.0) 6 (31.5) 2 (10.5) 9 7 (77.8) 2 (22.2) 0 (0.0)
Mock vaccinated 12 9 (75.0) 2 (16.7) 1 (8.3) 6 6 (100) 0 (0.0) 0 (0.0)
Vaccinated 16 3 (18.7)* 5 (31.3) 8 (50.0)† 6 1 (16.7)‡ 4 (66.6) 1 (16.7)
a “Recovering” refers to animals that developed transient infection and were in complete or partial remission at the end of follow-up. “Healthy” refers to animals that showed no
signs of disease during the observation period. *, Statistically different from naive and mock-vaccinated animals at P
 0.027 and P
 0.004, respectively; †, statistically different
from naive and mock-vaccinated animals at P
 0.015 and P
 0.027, respectively; ‡, statistically different from naive and mock-vaccinated animals at P
 0.024 and P
 0.004,
respectively.
FIG 5 Outcome of challenge performed with 10 LD50s of HSV-2. Animals
were vaccinated (LAW-gB1) or mock vaccinated (LAW) with vector particles
pseudotyped with VSV-G. (A) Percentages of animals that remained disease-
free throughout the observation period. (B) Percentages of surviving animals.
The numbers of dead animals were calculated as in Fig. 4. n, Number of ani-
mals/group. An asterisk indicates a significant difference relative to vaccinated
animals at P 0.003.
TABLE 2 Results of tests carried out to examine whether eight
vaccinated animals, which showed no signs of disease after HSV-2

















Sick (5) 3 5 5/3 5
Transiently
infected (5)
0 5 3/1 5
Healthy (8) 0 2 2/1ef 2f
a That is, animals that either were still sick, were transiently infected and fully
recovered, or never showed signs of disease by the end of follow-up.
b That is, the number of HSV-2 nested PCR-positive animals. Analysis was performed
in cervical epithelial cells collected at the end of follow-up.
c That is, the number of animals positive for anti-HSV antibody as determined by WB
analysis of sera collected at day 30 p.c. The sera of HSV-2-infected or gB1-vaccinated
animals were used as positive or negative controls, respectively. Six healthy animals
were positive for gB1 antibody only.
d That is, the number of animals diseased/number of animals dead after HSV-2
reactivation induced by deep immunosuppression by CY inoculation at day 80 p.c.
e That is, the number of HSV-2 nested PCR-positive animals. Analysis was performed
in sciatic nerve and cervical ganglia collected at day 21 post-CY inoculation.
f Significantly different from sick naive controls at P
 0.013.
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vLAW-gB1/VSV-vaccinated (and therefore positive for gB1-Ab
only) mice served as negative controls, while positive controls
were sera from symptomatic naive and vaccinated mice. As ex-
pected, all of the latter sera showed WB profiles with multiple
bands typical of a full-blown HSV-2 infection. In contrast, six of
the vaccine protected animal sera showed the gB1-Ab band alone,
and only two had an extended, albeit weakWB reactivity (Table 2
and data not shown). This suggested that in some animals the
vaccine had prevented not only the clinical emergence of the in-
fection but also the infection itself.
To address this aspect more in depth, at 80 days p.c. the eight
vaccine-protected mice, as well as some vaccinated and naive an-
imals of the same experiment that had developed and then re-
solved signs of HSV-2 disease postchallenge, were given a bolus of
cyclophosphamide (CY). This treatment depleted by ca. 90% the
circulating lymphocytes of the mice within 1 day and left them
strongly leukopenic for more than 2 weeks (data not shown), cre-
ating conditions favorable for the reactivation of a latent HSV-2
infection. In the five naive animals that had resolved the disease,
reactivation was indeed immediate: all again developed HSV-2
lesions starting 2 days post-CY and 3 died by day 11. Infection also
reactivated in three of five of the vaccinees that had transiently
exhibited viral lesions postchallenge. In these mice, however, the
clinical relapses occurred later (days 4 to 7 post-CY) and were
generally more benign compared to the relapses occurred in the
former animals. One of these animals died at day 15 post-CY, but
the death was deemed unrelated to the HSV-2 since the clinical
score never exceeded 2 and the conditions had been stable for
almost 1 week. Of the eight vaccine-protected mice, the same six
animals that showed the gB1-Ab band alone remained disease-
free throughout the observation period of 3 weeks, one developed
a mild genital erythema that appeared at day 4 and lasted 1 week,
and one remained healthy until day 9 post-CY but then developed
severe and rapidly progressive signs of HSV-2 disease which led to
its euthanasia at day 15 post-CY. Statistical analysis showed that
reactivation was significantly less frequent in the vaccine-pro-
tected animals than in the naive animals at P 
 0.013. Finally, at
the end of the experiment, all surviving animals were sacrificed,
and their sciatic nerves and cervical ganglia PCR were examined
for the presence of the HSV-2 genome. All animals that had un-
dergone clinical reactivation tested positive, and the samewas true
for two vaccinees that had been transiently sick postchallenge but
had not reactivated the infection post-CY. In contrast, the six vac-
cine-protected animals that were gB1-Ab positive only and had
remaineddisease free even post-CY tested negative. The difference
between the rate of PCR positivity in the vaccine-protected and
naive animals was also statistically significant (Table 2).
Dissection of the immune responses elicited by vLAW-gB1/
VSV. In the present study, 15 mice per group were either vacci-
nated with vLAW-gB1/VSV or mock vaccinated with vLAW/VSV
and examined for gB1-Ab, HSV-1 and HSV-2 NAb, and gB1-TL
in the blood, spleen, bone marrow, and iliac lymph nodes accord-
ing to the standard schedule depicted by Fig. 2. The mock vaccinees
were constantly negative in all of the assays, while examination of
the vaccines revealed some interesting findings. The kinetics and
level of gB1-Ab and gB1-TLwere very similar to those illustrated
by Fig. 3 and are therefore not further described. The NAbs in the
sera were detectable from the second sampling (1 week after first
immunizing dose) onward and were inhibitory for both HSV-1
and HSV-2, albeit with different efficacies; typically, sera diluted
1:10 reduced plaque formation by HSV-1 and HSV-2 by 70 and
60%, respectively, and, although higher dilutions were increas-
ingly less effective, marginal neutralizing activity was observed up
to a dilution of 1:80 (Fig. 6A and data not shown). Similarly to
what is depicted in Fig. 3 and despite the fact that the third immu-
nizing dose had led to a substantial increment of gB1-Ab, the
neutralizing activity of sera underwent only a marginal increase.
Indeed, the combined ANOVA-Tukey’s test found that only the
difference between means at 7 and 14 days postvaccination and at
7 and 42 days postvaccination were statistically significant at P
0.005. Comparison of themeans at 14 and 42 days postvaccination
did not reach statistical significance.
In the vaccinees, gB1-TL were present in all of the lymphoid
tissues examined, but their development followed different kinet-
ics depending on the organ. In the spleen, these cells were already
rather abundant (ca. 15%) after the first immunization and then
remained essentially stable throughout the experiment. The bone
marrow after the first immunization also had elevated propor-
tions of these effectors, which further increased after the second
dose of immunogen to return to the previous levels at the time of
challenge. In contrast, the iliac lymph nodes contained very few if
any gB1-TL after the first dose but at later times exhibited the
largest values that were observed in the study (ca. 30%). The com-
bined ANOVA-Tukey’s test showed no statistical significance be-
tweenmeans of spleen and bonemarrow tissues at any time tested.
In contrast, in iliac lymph nodes the difference between means at
7 and 14 days postvaccination and at 7 and 42 days postvaccina-
tion reached statistical significance at P	 0.001 (Fig. 6B). Again,
there was no statistical significance between means at 14 and 42
days postvaccination.
DISCUSSION
Genital infections caused by HSV-1 and HSV-2 are exceedingly
common, spread at an unrelenting pace, and increase host suscep-
tibility to other sexually transmitted infections (10, 41, 67). De-
spitemany efforts in vaccine development and several clinical tests
(5, 14, 27), no truly effective measures to prevent infection or
disease are currently available (17, 38).
To address this issue, we focused on gB1. This HSV-1 envelope
glycoprotein has several qualifying features as a vaccinal immuno-
gen. (i) Together with other glycoproteins (7, 55, 57), gB1 medi-
ates HSV-1 entry into susceptible cells. Its cellular receptor is the
nonmusclemyosin heavy chain IIA (NMHC-IIA), a subunit of the
nonmuscle myosin IIA (NM-IIA) (3). Because of its essential role
in cell adhesion, cell migration, and tissue architecture (62), NM-
IIA is expressed in various tissues and cell types in vivo and may
thus favor the broad spectrum of HSV-1 infection (7). Specific
immune responses blocking gB1-NMHC-IIA interplay could
therefore greatly reduce viral infectivity. (ii) gB1 induces strong
humoral and cell-mediated immune responses (17, 35). (iii) It
contains “protective” cytotoxic-T-lymphocyte (CTL) epitopes
that are preferentially recognized by asymptomatic subjects, are
important to prevent recurrent diseases, andmaintain HSV-1 in a
latent state (12, 45). (iv) Finally, gB1 is highly conserved within
and between HSV-1 and HSV-2 serotypes. The interserotype ho-
mology is 85% at amino acid level and, with the exception of theN
andC-terminal regions, the secondary structure is also highly sim-
ilar (6). As a consequence, HSV-1 and HSV-2 gB share several B-
and T-lymphocyte epitopes that induce cross-reactive NAb and
CTL responses in both natural and experimental infections (35,
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51) and have allowed the development of cross-neutralizing anti-
bodies (29).
Thus, vaccinations with HSV-1 and HSV-2 gB have been at-
tempted in many ways by using the whole gene either as a protein
or as a DNA coding sequence (9, 14), selected immunodominant
T-lymphocyte epitope(s) as peptides or DNA sequences (39, 44),
and various delivery systems and immunization routes (28, 36).
Finally, gB was tested either alone or combined with other HSV
immunogens (18, 34, 64). In general, these vaccines, whether
tested in animal models or clinical studies, prevented HSV-1 dis-
ease but were poorly protective against lethal doses of HSV-1 and
were clearly inadequate against HSV-2. The studies also showed
thatmucosal immunity is important to prevent or curb the course
of infection (17, 27, 30, 38).
The novelty of our study is the delivery of gB with a lentiviral
vector that, to the best of our knowledge, has never been used as a
vaccine vector against HSV. Lentiviral vectors are well suited to
stimulate immunity. Compared to other vectors and most adju-
vants, lentiviruses also transduce nondividing cells, including
dendritic cells (DCs) andmacrophages (26), thus setting the basis
for an efficient stimulation of the immune system. Here, we used
LAW34, an FIV vector complying with today’s safety standards
(19) and tested in various animal species (cats, mice, pigs, and
rats). A concern with any lentiviral vector is the potential conse-
quence of the integration of their genomes into the host’s DNA.
To overcome this possible risk, the use in vaccine development of
integrase-deficient lentiviral vectors has been proposed with
promising results (15, 37). This may represent an interesting ave-
nue for future studies. Possibly because the long terminal repeat of
LAW34 are inactivated, in more than 3 years of follow-up studies
lasting a few weeks to several months and dozens of animals inoc-
ulated, neither short- nor long-term noxious effects were ob-
served. In one of these studies, porcine cardiac stem cells were
transduced ex vivo, implanted in rats with myocardial infarction,
and monitored for 3 months by nuclear magnetic resonance im-
aging. The cells survived, differentiated, and expressed the trans-
duced reporter gene throughout the observation period, a clear
indication that LAW34 does not harm or affect physiological
functions of implanted cells and the delivered gene is expressed for
protracted periods of time (8). The use of LAW34 for vaccination
was prompted by an earlier study in which we demonstrated that
this vector transduced DCs very efficiently when pseudotyped
with RD/114 (43). Since DCs play a key role in building up the
adaptive host defense against an invading pathogen (54), we ex-
pected this vector makeup to be better than conventional pseu-
dotypingwithVSV-G. Surprisingly, the results demonstrated oth-
erwise. Although vLAW-gB1/RD induced prompter immune
responses, these declined faster compared to vLAW-gB1/VSV so
that both vaccine groups had equivalent anti-gB1 immune re-
sponses at the time of challenge. Even more disappointingly,
FIG 6 Analysis of anti-HSV immune responses in vaccinated (LAW-gB1) and mock-vaccinated (LAW) animals. The timeline of the vaccination schedule and
testing for elicited immune responses is as described in Fig. 2. (A) Percentages of anti-HSV-1 (circles)- and anti-HSV-2 (triangles)-neutralizing activity in sera
collected at the indicated times and tested at 1:10 (solid symbols) and 1:20 (empty symbols) dilution. The percent neutralization refers to the number of infected
cells incubated with the virus alone. Serum samples from naive animals diluted 1:10 showed a neutralization activity of10%. An asterisk indicates a statistically
significant increment at P 0.005. (B) Percentages of gB1-TL from spleen (circles), iliac lymph nodes (triangles), or bone marrow (squares) as measured by
intracellular staining after stimulation with gB1 T epitope (solid symbols) or scrambled peptide (empty symbols). Analysis was performed in animals euthanized
at the indicated times. The dotted line indicates the cutoff. The solid line indicates the average value. IFN--secreting CD4 T lymphocytes were below cutoff or
undetectable. **, Statistically significant increment at P	 0.001.
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vLAW-gB1/RD afforded no protection againstHSV-1 challenge. In
contrast, the vLAW-gB1/VSV vaccinees were fully protected from
disease, paralleling the results obtained from most HSV vaccines
hitherto developed (17, 38).
As in previous vaccine studies (17, 27), HSV-2 was more
pathogenic and difficult to contain by immunological measures
compared to HSV-1. At 1 LD50, the HSV-2 isolate yielded symp-
tomatic infection in all naive and mock-vaccinated animals and
killed more than 60% of the animals. In most of these, death was
preceded by paralysis starting from hind limbs and rapidly ex-
tending to the back, suggesting a pronounced neurovirulence of
the isolate. Vaccination, which was performed only with vLAW-
gB1/VSV, spared 75 and 80% of the animals from severe infection
and death, respectively. We then wanted to ascertain whether the
8 of 16 vaccinees, which showed no signs of disease, not even
transient redness at the site of challenge, were fully protected or
underwent subclinical infection. This was investigated through
several approaches. Searching for the viral genome in vaginal
brushes by real-time or nested PCR proved to be not sufficiently
sensitive. HSV recurrence induction by CY treatment and PCR
analysis of nervous tissues proved to be a more effective way to
determine infection. These methods allowed us to identify the
virus in all controls that were sick following challenge but fully
recovered before CY treatment. As frequently observed in patients
(51), severity of recurrences were proportional to postchallenge
clinical onset; in animals where primary infection was severely
debilitating and prolonged, HSV-2 reactivated sooner and caused
comparable or worse disease. In contrast, of the animals that had
had mild primary infection, two had no clinical relapse and yet
were determined to be HSV positive by PCR in nervous system
tissues, and three had a modest and transient clinical episode.
Among the eight fully protected animals, as judged by the absence
of clinical signs postchallenge, only two were, in fact, infected,
whereas there was no trace of the virus in the remaining vaccinees.
In all, vLAW-gB1/VSV was able to protect from HSV-2 infection
and severe disease, as defined by clinical score 2 or higher, 38 and
80% animals, respectively, thus outperforming most previously
developed vaccines based on the sole gB (14, 27). Protection effi-
cacy was further addressed against a challenge dose 10 times
higher than in the above tests and that killed nearly all of the naive
and mock-vaccinated controls. Although the number of animals
used in this experiment was low, vaccination spared 50 and 83%
animals from severe infection and death, respectively.
The type and extent of elicited immunity was investigated by
measuring gB1-Ab and virus NAb in serum, gB1-TL in bone
marrow and spleen, and, given their importance in prevention
and immune control of viral latency and reactivation of genital
herpes infection (68), iliac lymph nodes. These parameters were
monitored in vaccinated and mock-vaccinated animals 1 week
after first and second immunizations and at challenge, i.e., 3 weeks
after the third immunization. Although we detected anti-gB1 IgA
in vaginal washes and serum, we were not able to clearly discern
them from IgG. Given the undisputed importance of IgA against
mucosal infections in the genital tract (49), this is a limitation of
this work. Interestingly, and in contrast to our expectations for
immunization with lentiviral vectors, which are usually advanta-
geous to Th1 responses (26), vaccination elicited a prompt, po-
tent, and stable NAb response that was able to neutralize ca. 50%
HSV-1 andHSV-2. Although there are limited studies where NAb
and cross-neutralization activity aremeasured, our results were in
line with vaccination experiments carried out with DNA vaccines
encoding a gB1-secreting form (9) or combined with Th2-stimu-
lating compounds (28) or multi-epitope peptides (64). In our
study, NAb became detectable after the second immunization.
Similar behavior was observed for gB1-TL in iliac lymph nodes
as opposed to the bone marrow and spleen, where gB1-TL was
already measurable after the first immunization and gradually in-
creased thereafter. Despite the different kinetics, the percentages
of gB1-TL at challenge were high and at comparable levels in the
three body sites and were similar to those observed in previous
studies addressing the role of cell-mediated immune response
against vaginal and systemic HSV-2 infections (56, 65, 68).
Taken together, these results demonstrate that vLAW-gB1/
VSV favorably compares to most HSV reference vaccines. Immu-
nization was accomplished with three inoculations of vLAW-gB1/
VSV (106 TU/dose), an amount easy to produce and scale up, and
by using a single immunogen. A larger dosemight have beenmore
effective but would have been difficult to scale up for human use.
Since LAW34 can stably deliver two ormore genes for up to 7 kb of
heterologous DNA (61), this vaccine has ample room for im-
provement. Indeed, we are already testing in vitro LAW34 deliv-
ering gB and gD, another HSV receptor extensively used for vac-
cination (17, 38, 65), and gB and ICP27, a multifunctional early
regulatory protein eliciting strong and protective cell-mediated
immune responses (32). With a truly protective vaccine years
away (5), LAW34, either administered alone or combined with
other delivery systems, may become a structural component of an
effective vaccine against the genital herpes. Further studies in this
and other animal models are clearly worthwhile to confirm the
protective efficacy of LAW34 and investigate in greater depth the
immunological bases of this protection.
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